Scientific deep-dive
Is It Just the Weight Loss?
Every benefit reported for these drugs runs into the same question. A post hoc analysis of the SURMOUNT-OSA trials tried to separate the drug from the weight, and found the sleep apnea improvement doing work of its own.
Every benefit reported for these drugs runs into the same question: is this the medicine, or is it just the weight coming off? A post hoc mediation analysis of the SURMOUNT-OSA trials tried to separate the two, and concluded that treating both the sleep-disordered breathing and the obesity is likely needed to get the full cardiometabolic benefit.[1] That conclusion comes from modeling, and the modeling has limits.
Why the question is hard
When someone with obstructive sleep apnea takes tirzepatide, several things change at once. They lose weight. Their apnea-hypopnea index falls. Their overnight oxygen levels improve. And their inflammatory markers, insulin resistance and blood pressure all move in the right direction.
Establishing which change drove which is not something a trial answers by design, because the trial randomized only the drug, not the weight loss or the apnea improvement. Mediation analysis is the statistical attempt to decompose it after the fact: given how much each intermediate changed, how much of the final outcome moves with it?
What the analysis found
Across both 52-week studies in the SURMOUNT-OSA program, tirzepatide improved cardiometabolic risk factors more than placebo. The mediation results then split into three distinct patterns.
| Outcome | Mediated by sleep apnea metrics? | Mediated by weight? |
|---|---|---|
| hs-CRP (inflammation) | Yes, independently | Not reported as an independent effect |
| HOMA-IR (insulin resistance) | Yes, independently | Not reported as an independent effect |
| Triglycerides | Yes, independently | Not reported as an independent effect |
| Systolic blood pressure | In combination with weight | Yes, weight alone as well |
| Diastolic blood pressure | No | No |
The first three rows are the interesting ones. Inflammation, insulin resistance and triglycerides showed an independent mediation effect from the sleep apnea measures. The model attributes part of their improvement to breathing better at night, over and above what the weight loss accounts for.
In the model, part of the improvement in inflammation, insulin resistance and triglycerides ran through better breathing at night, beyond what the weight loss accounted for.
That is an argument against “it is all just the weight loss”, but a modeling argument rather than a demonstration. A far larger prespecified analysis has since reached the same conclusion for the heart, in 17,604 people against a hard endpoint: losing weight predicted more heart attacks. That result also undercuts a model that projected heart benefit from risk-factor changes alone.
What mediation analysis can and cannot show
Two further cautions belong with that. Parts of this work were post hoc, including the insulin-resistance analysis and the mediation analysis itself, as the paper states. And the published abstract reports which effects were significant without reporting how much of each outcome was mediated, so we cannot tell you whether sleep apnea accounted for a large share of the inflammation improvement or a small one. We are not going to estimate it.
The author disclosures on this paper are dense with industry relationships, Eli Lilly among them, as declared in the publication. For a manufacturer-sponsored analysis of a manufacturer-sponsored trial, that is expected, and readers should still know it.
The blood pressure result nobody has explained
Systolic pressure was mediated by weight, and by weight combined with the sleep apnea measures. Diastolic pressure was mediated by neither: not weight, not the apnea metrics, and not the combination.
Diastolic pressure did change. It simply was not explained by either intermediate the analysis examined, which leaves an open question rather than a finding: something about the treatment moved it that this decomposition did not capture. We report that as unresolved and do not offer a mechanism for it.
What it means practically
- Sleep apnea is worth treating on its own terms, not only as something weight loss will eventually fix. If the modeling is right, part of the metabolic benefit runs through the breathing.
- Stopping CPAP because the weight came off may forfeit something. This analysis gives a reason to think the two interventions are not interchangeable, though it does not test that directly.
- “It is just the weight loss” is too simple a story, and so is any confident claim about exactly how much of the benefit is not.
Frequently Asked Questions
References
- 1.Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial Nature Medicine. 2026. PMID: 41540105.
Compare the sellers
Related research
A Biomarker Is Not an Outcome
Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.
8 min read
Losing Weight Predicted More Heart Attacks
A prespecified analysis of 17,604 people found semaglutide's cardiovascular protection largely independent of weight lost. In the placebo arm, losing weight predicted more cardiac events.
7 min read
The Thing That Makes Regain Inevitable
Metabolic adaptation is the leading explanation for why weight loss plateaus and returns. A study asked whether tirzepatide interrupts it. In mice it did; in people it did not.
7 min read
Why the Appetite Comes Back
Weight loss slows and appetite for particular foods creeps back. A Science study found a specific brain circuit doing exactly that, in mice, whose neurons can be switched off with light.
6 min read
What GIP Does on Its Own
Tirzepatide's advantage is usually credited to its GIP component. Researchers infused native GIP for six weeks, raising total GIP in the blood about thirtyfold, and blood sugar did not improve.
7 min read
A Weight Drug for Having Too Little Fat
Lipodystrophy is the opposite of obesity: people are missing fat tissue, and are severely metabolically ill because of it. In a cohort given tirzepatide, those with familial partial lipodystrophy cut their daily insulin by a median of 109 units.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HealthRX
Compounded semaglutide at $165/month after a $99 first month
From $165/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →